GSA Capital Partners LLP Trims Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

GSA Capital Partners LLP lowered its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 95.5% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 27,350 shares of the company's stock after selling 578,313 shares during the quarter. GSA Capital Partners LLP's holdings in Xeris Biopharma were worth $78,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in shares of Xeris Biopharma by 7.3% during the first quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company's stock valued at $16,810,000 after acquiring an additional 519,897 shares during the last quarter. Renaissance Technologies LLC raised its stake in Xeris Biopharma by 33.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company's stock valued at $3,041,000 after purchasing an additional 342,300 shares during the last quarter. Rosalind Advisors Inc. lifted its holdings in Xeris Biopharma by 10.6% in the 2nd quarter. Rosalind Advisors Inc. now owns 3,120,170 shares of the company's stock valued at $7,020,000 after purchasing an additional 300,000 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Xeris Biopharma by 23.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 428,554 shares of the company's stock worth $964,000 after purchasing an additional 80,015 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Xeris Biopharma by 4.6% during the second quarter. AQR Capital Management LLC now owns 1,193,080 shares of the company's stock worth $2,684,000 after buying an additional 52,074 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company's stock.

Xeris Biopharma Stock Performance

Shares of NASDAQ XERS traded up $0.10 during trading on Tuesday, hitting $3.18. 1,321,918 shares of the company were exchanged, compared to its average volume of 1,710,077. The company has a fifty day moving average price of $3.04 and a 200-day moving average price of $2.60. The firm has a market capitalization of $474.07 million, a PE ratio of -7.07 and a beta of 2.70. Xeris Biopharma Holdings, Inc. has a 12-month low of $1.69 and a 12-month high of $3.64.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on XERS shares. Piper Sandler downgraded shares of Xeris Biopharma from an "overweight" rating to a "neutral" rating and set a $3.00 price target on the stock. in a research note on Monday, November 11th. HC Wainwright raised their target price on shares of Xeris Biopharma from $6.00 to $6.60 and gave the stock a "buy" rating in a research note on Monday, November 11th.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.